NextCell’s daughter company Cellaviva granted permission to handle amniotic tissue

April 22, 2024

NextCell Pharma AB ("NextCell" or the "Company") today announces that the Swedish Health and Social Care Inspectorate (IVO) has granted their Cellaviva tissue establishment permission to handle amniotic tissue. Cellaviva is the largest private stem cell bank in the Nordics. Since the launch of the cord blood bank in 2014, the company has increased the business model to include genetic tests and tissue handling services for biotech companies and hospitals.

Cellaviva is expanding business-to-business activities by broadening their tissue establishment permission to include aminiotic tissues. This opens up the opportunity for handling ophthalmic products which often are produced from amniotic tissue. Discussions potential suppliers are ongoing. The business model is fee for service. Cellaviva provides a service for handling, shipping and traceability of tissues which require a tissue establishment.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company that is in phase 2 studies with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase 3 study. ProTrans is manufactured utilizing the patented platform technology for selection of optimal cells with potency to treat inflammatory disorders including autoimmune diseases. NextCell owns Cellaviva, the largest stem cell bank in the Nordics and QVance, a quality analysis CRO company in upstart.

Download attachment Read full press release on Cision (external link)

2024-02-14

NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy

Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.

Read more Read more

2024-01-25

NextCell publishes its Interim Report 1 2023/2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2024-01-24

Updates regarding NextCell’s Clinical Trials with ProTrans

NextCell Pharma has several ongoing clinical trials with ProTrans. The largest ongoing study ProTrans Young, which includes 66 patients, is progressing well. All 30 patients in the older age group have been recruited and will be treated with ProTrans. In the long-term follow-up studies ProTrans-Obs and ProTrans-Repeat the first diabetes patients have now completed the studies after five years of follow-up.

Read more Read more

2023-12-13

NextCell Pharma has compiled a Q&A section

NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section. The questions and answers can be accessed via the link below.

Read more Read more

2023-11-06

Repeated treatment with ProTrans is immunologically safe

NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.

Read more Read more

2023-10-26

NextCell publishes its Year-End Report 2022/2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2023-10-10

NextCell signs an agreement for a new tissue product

NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.

Read more Read more

2023-09-05

NextCell Pharma presents at the Advanced Therapies Europe conference

NextCell Pharma participates in Advanced Therapies Europe, a European conference in Portugal on advanced cell therapies. NextCell's CSO Dr. Lindsay Davies will talk about NextCell's platform technology and the internationally recognized research generated during the development of drug product ProTrans for type 1 diabetes.

Read more Read more